CMS caps out-of-pocket insulin costs for Medicare

CMS is capping out-of-pocket insulin costs for Medicare beneficiaries at $35 per month, the agency said May 26. 

More than 1,750 standalone Medicare Part D prescription drug plans will offer the lower insulin copays through the Part D Senior Savings Model for the 2021 plan year. 

The $35 per month cap applies to both pen and vial dosage forms for rapid-acting, short-acting, intermediate-acting and long-acting insulin.

More than 3.3 million Medicare beneficiaries use one or more common forms of insulin, and they could see annual savings of about $446 for insulin, CMS said in a news release.

More articles on pharmacy:
AstraZeneca gets $1B from US to produce COVID-19 vaccine
7 things to know about startup drugmaker Phlow
Consumers still feel comfortable picking up prescriptions at pharmacies, survey says

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars